tradingkey.logo

Pluri Inc

PLUR
3.400USD
-0.140-3.95%
Cierre 11/05, 16:00ETCotizaciones retrasadas 15 min
26.84MCap. mercado
PérdidaP/E TTM

Más Datos de Pluri Inc Compañía

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Información de Pluri Inc

Símbolo de cotizaciónPLUR
Nombre de la empresaPluri Inc
Fecha de salida a bolsaDec 10, 2007
Director ejecutivoMr. Yaky Yanay
Número de empleados106
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 10
DirecciónMatam Advanced Technology Park
CiudadHAIFA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal3508409
Teléfono972747108600
Sitio Webhttps://pluri-biotech.com/
Símbolo de cotizaciónPLUR
Fecha de salida a bolsaDec 10, 2007
Director ejecutivoMr. Yaky Yanay

Ejecutivos de Pluri Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yaky Yanay
Mr. Yaky Yanay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
328.24K
+13.50%
Mr. Zalman (Zami) Aberman
Mr. Zalman (Zami) Aberman
Chairman of the Board
Chairman of the Board
142.86K
+1.52%
Mrs. Liat Zalts
Mrs. Liat Zalts
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
28.77K
-67.72%
Ms. Maital Shemesh-Rasmussen
Ms. Maital Shemesh-Rasmussen
Independent Director
Independent Director
8.58K
+24.63%
Mr. Rami Levi
Mr. Rami Levi
Independent Director
Independent Director
--
--
Mr. Lorne Abony
Mr. Lorne Abony
Director
Director
--
--
Mr. Alejandro Weinstein M., CPA
Mr. Alejandro Weinstein M., CPA
Non-Executive Director
Non-Executive Director
--
--
Mr. Eitan Ajchenbaum
Mr. Eitan Ajchenbaum
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yaky Yanay
Mr. Yaky Yanay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
328.24K
+13.50%
Mr. Zalman (Zami) Aberman
Mr. Zalman (Zami) Aberman
Chairman of the Board
Chairman of the Board
142.86K
+1.52%
Mrs. Liat Zalts
Mrs. Liat Zalts
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
28.77K
-67.72%
Ms. Maital Shemesh-Rasmussen
Ms. Maital Shemesh-Rasmussen
Independent Director
Independent Director
8.58K
+24.63%
Mr. Rami Levi
Mr. Rami Levi
Independent Director
Independent Director
--
--
Mr. Lorne Abony
Mr. Lorne Abony
Director
Director
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Merchant Adventure Investment Advisors, LLC
16.24%
Chutzpah Holdings Ltd
11.42%
Plantae Bioscience Ltd
5.55%
Shayna LP
4.99%
Yanay (Yaky)
4.02%
Otro
57.77%
Accionistas
Accionistas
Proporción
Merchant Adventure Investment Advisors, LLC
16.24%
Chutzpah Holdings Ltd
11.42%
Plantae Bioscience Ltd
5.55%
Shayna LP
4.99%
Yanay (Yaky)
4.02%
Otro
57.77%
Tipos de accionistas
Accionistas
Proporción
Corporation
21.96%
Investment Advisor
16.51%
Individual Investor
14.41%
Hedge Fund
0.65%
Investment Advisor/Hedge Fund
0.03%
Research Firm
0.02%
Otro
46.42%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
48
1.60M
19.60%
+24.19K
2025Q2
63
4.98M
63.33%
+517.44K
2025Q1
65
3.71M
58.06%
+1.86M
2024Q4
67
2.02M
30.36%
+246.73K
2024Q3
68
1.79M
28.64%
+229.71K
2024Q2
74
1.75M
29.65%
+364.60K
2024Q1
75
1.84M
31.64%
+644.62K
2023Q4
83
1.69M
28.85%
+375.55K
2023Q3
92
1.44M
29.22%
+173.51K
2023Q2
98
1.07M
24.55%
+213.90K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Merchant Adventure Investment Advisors, LLC
1.32M
16.24%
+49.63K
+3.89%
Sep 16, 2025
Chutzpah Holdings Ltd
931.25K
11.42%
-453.98K
-32.77%
Sep 16, 2025
Plantae Bioscience Ltd
452.70K
5.55%
--
--
Sep 16, 2025
Shayna LP
419.26K
5.14%
+1.00
+0.00%
May 27, 2025
Yanay (Yaky)
289.19K
3.55%
+28.21K
+10.81%
Sep 16, 2025
Gunn (John A)
307.25K
3.77%
--
--
Sep 16, 2025
Slager (David M)
290.76K
3.56%
+194.49K
+202.03%
May 27, 2025
Aberman (Zalman)
142.86K
1.75%
+2.14K
+1.52%
Sep 16, 2025
Franco-Yehuda (Chen)
40.06K
0.49%
--
--
Sep 16, 2025
Zalts (Liat)
28.77K
0.35%
-60.34K
-67.72%
Sep 16, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
DFA Dimensional International Small Cap ETF
0%
DFA Dimensional International Small Cap ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
Fecha
Tipo
Relación
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
Mar 27, 2024
Merger
8→1
KeyAI